The Only Monthly Membership With a Positive ROI!
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
The Only Monthly Membership With a Positive ROI!
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Joshua E. Schimmer
Biogen Is A Frustrating Case, And Piper Jaffray Hopes It Doesn't Regret Upgrade
Biogen Drug 'Increasingly Vulnerable,' Analyst Warns After Speaking With MS Expert
MannKind's Future Looks 'Grim,' Has 37% Downside Warns Piper Jaffray
Biogen Drug 'Increasingly Vulnerable,' Analyst Warns After Speaking With MS Expert
MannKind's Future Looks 'Grim,' Has 37% Downside Warns Piper Jaffray
ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray
Analyst Sees Upside To Outlook At 4 Biotechs
ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray
Analyst Sees Upside To Outlook At 4 Biotechs
UPDATE: Piper Jaffray Initiates Coverage On Lion Biotechnologies Based On DCF Analysis
UPDATE: Piper Jaffray Upgrades ISIS Pharmaceuticals Following Mixed 1Q Results
Read More...
Joshua E. Schimmer Recent News
UPDATE: Piper Jaffray Initiates Coverage on Regeneron Pharmaceuticals as 2014 Biotech Sector Outlook Remains Strong
UPDATE: Piper Jaffray Initiates Coverage on Vanda Pharmaceuticals on Expected Attractive Returns
UPDATE: Piper Jaffray Initiates Coverage on Pharmacyclics as 2014 Biotech Sector Outlook Remains Strong
UPDATE: Piper Jaffray Initiates Coverage on MannKind on Expected Attractive Returns
UPDATE: Piper Jaffray Initiates Coverage on Incyte as 2014 Biotech Sector Outlook Remains Strong
UPDATE: Piper Jaffray Initiates Coverage on Gilead Sciences on Expected Attractive Returns
UPDATE: Piper Jaffray Resumes Coverage on Celgene as 2014 Biotech Sector Outlook Remains Strong
UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical on Expected Attractive Returns
UPDATE: Piper Jaffray Resumes Coverage on Biogen Idec as 2014 Biotech Sector Outlook Remains Strong
UPDATE: Piper Jaffray Initiates Coverage on Amgen on Expected Attractive Returns
UPDATE: Piper Jaffray Initiates Coverage on Alexion Pharmaceuticals as 2014 Biotech Sector Outlook Remains Strong
UPDATE: Piper Jaffray Initiates Coverage on Nektar Therapeutics on Expected Attractive Returns
UPDATE: Piper Jaffray Initiates Coverage on Insmed as 2014 Biotech Sector Outlook Remains Strong
UPDATE: Piper Jaffray Initiates Coverage on GW Pharmaceuticals on Expected Attractive Returns
UPDATE: Piper Jaffray Initiates Coverage on Chimerix as 2014 Biotech Sector Outlook Remains Strong
UPDATE: Piper Jaffray Initiates Coverage on Repros Therapeutics on a Cleaner Approach to Male Hypogonadism
UPDATE: Piper Jaffray Assumes Coverage on ISIS Pharmaceuticals as Company's Antisense Platform Continues to Advance